Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.

PURPOSE Multiplex genomic tests are enabling oncologists to interrogate the DNA of their patients. However, few oncologists are proficient with respect to the implications of complex molecular diagnostics. We initiated a Molecular Tumor Board that focused on individual patients with advanced cancer whose tumors underwent genomic profiling, and here report our experience with breast cancer. METHODS A multidisciplinary team that included physicians, scientists, geneticists, and bioinformatics/pathway specialists attended. All molecular tests were performed in a Clinical Laboratory Improvement Amendments environment (next-generation sequencing, 182 or 236 genes). RESULTS Forty of 43 patients (93%; mean age, 59 years) had at least one theoretically actionable aberration (mean, 4.79 anomalies/patient). Median time from ordering to report was 27 days (median of approximately 11 days for specimen acquisition and approximately 14 days for diagnostic processing). Even if we considered distinct abnormalities in a gene as the same, there were only two patients with an identical molecular profile. Seventy-three genes (206 abnormalities; 119 distinct) were aberrant. Seventeen of the 43 patients (40%; median, seven previous therapies in the metastatic setting) were treated in a manner consistent with Molecular Tumor Board discussions; seven (16% of 43, or 41% of 17) achieved stable disease for 6 or more months (n = 2) or partial remission (n = 5). Lack of access to targeted medication was the most common reason that patients could not be treated. CONCLUSION Multidisciplinary molecular tumor boards may help to optimize the management of patients with advanced, heavily pretreated breast cancer who have undergone genomic testing. Facilitating availability of appropriately targeted drugs and clinical trials is needed.

[1]  R. Yelensky,et al.  Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms , 2014, Oncotarget.

[2]  J. Lee,et al.  Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. , 2014, Cancer research.

[3]  O. Stål,et al.  High‐resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1 , 2011, Genes, chromosomes & cancer.

[4]  J. Manyika,et al.  Disruptive technologies: Advances that will transform life, business, and the global economy , 2013 .

[5]  A. Cheng,et al.  Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells , 2013, Cell Death and Disease.

[6]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[7]  G. Hortobagyi,et al.  Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2. , 2013 .

[8]  G. Kroemer,et al.  Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma , 2004, Apoptosis.

[9]  L. Gordon,et al.  Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. , 2012, Antiviral research.

[10]  B. Katzenellenbogen,et al.  Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. , 1996, Molecular endocrinology.

[11]  M. Hall Conflicted confidence: academic oncologists' views on multiplex pharmacogenomic testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[13]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Zucchetti,et al.  Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Jane C Weeks,et al.  Physicians' attitudes about multiplex tumor genomic testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Piccart,et al.  Emerging targeted agents in metastatic breast cancer , 2013, Nature Reviews Clinical Oncology.

[17]  Michael Bittner,et al.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Yuan Qi,et al.  Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers , 2012, Breast Cancer Research and Treatment.

[19]  R. Kurzrock,et al.  Cyclin alterations in diverse cancers: outcome and co-amplification network , 2014, Oncotarget.

[20]  S. Lippman,et al.  Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. , 2014, The oncologist.

[21]  Tingting Jiang,et al.  Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers , 2014, Breast Cancer Research and Treatment.

[22]  P. Stephens,et al.  A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. , 2014, The oncologist.

[23]  Xin Huang,et al.  High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Razelle Kurzrock,et al.  Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. , 2014, Cell reports.